Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL)

Issa F. Khouri, MD, Rima M Saliba, PhD, Zijun Y. Xu-Monette, PhD, Martin Korbling, MD, Gabriela Rondon, MD, Rosamar Valverde, Amin M. Alousi, MD, Paolo Anderlini, MD, Sairah Ahmed, MD, Stefan O Ciurea, MD, Luis Fayad, MD, Betul Oran, MD, Simrit Parmar, Uday R. Popat, MD, Jason R. Westin, MD, Francesco Turturro, MD, L. Jeffrey Medeiros, MD, Alison M Gulbis, PharmD, BCOP, Ken H. Young, MD PhD

Blood (2014) 124 (21): 2563.

https://doi.org/10.1182/blood.V124.21.2563.2563

Published: 2014

Journal Articles

Modified-CVAD Or Modified-Cbad Compared To High Dose Cyclophosphamide For Peripheral Blood Stem Cell Mobilization In Patients With Multiple Myeloma

Suzanne C Gettys, PharmD, Alison M Gulbis, PharmD, BCOP, Kaci Wilhelm, PharmD, BCOP, Yvonne T Dinh, Gabriela Rondon, MD, Muzaffar H. Qazilbash, MD

Blood (2013) 122 (21): 2036.

https://doi.org/10.1182/blood.V122.21.2036.2036

Published: 2013

Journal Articles

A Lower Dose Of Melphalan (140 mg/m 2 ) As Preparative Regimen For Multiple Myeloma In Patients >65 Or With Renal Dysfunction

Ila Maewal Saunders, PharmD, Alison M Gulbis, PharmD, BCOP, Richard E Champlin, MD, Muzaffar H. Qazilbash, MD

Blood (2013) 122 (21): 5536.

https://doi.org/10.1182/blood.V122.21.5536.5536

Published: 2013

Journal Articles

Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan ( 90 YIT)

Issa F. Khouri, MD, Rima M. Saliba, Ph.D., Zijun Y Xu-Monette, MD, Gabriela Rondon, MD, Rosamar Valverde, MD, Martin Korbling, MD, Alison M Gulbis, PharmD, BCOP, Paolo Anderlini, MD, Ahmed Sairah, MD, Chitra M. Hosing, MD, Uday R Popat, MD, Partow Kebriaei, MD, Luis E Fayad, Jason R. Westin, MD, Francesco Turturro, MD, L. Jeffrey Medeiros, MD, Richard E Champlin, MD, Ken H. Young, MD, PhD

Blood (2013) 122 (21): 3350.

https://doi.org/10.1182/blood.V122.21.3350.3350

Published: 2013

Journal Articles

Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis

Issa F. Khouri, MD, Rima M. Saliba, Ph.D., Pramoda Challagundla, Celina Ledesma, Martin Korbling, MD, Alison M Gulbis, PharmD, BCOP, Maria Guillermo-Pacheco, Sairah Ahmed, MD, Paolo Anderlini, MD, Qaiser Bashir, MD, Betul Oran, MD, Stefan O Ciurea, MD, Chitra M. Hosing, MD, Partow Kebriaei, MD, Uday R Popat, MD, Elias Jabbour, MD, Richard E Champlin, MD, Jeffrey L. Jorgensen, MD, PhD

Blood (2013) 122 (21): 3349.

https://doi.org/10.1182/blood.V122.21.3349.3349

Published: 2013

Journal Articles

Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosuppression

Issa F. Khouri, MD, Wei Wei, MS, Rosamar Valverde, MD, Martin Korbling, MD, Francesco Turturro, MD, Alison M Gulbis, PharmD, BCOP, Maria Guillermo-Pacheco, Sairah Ahmed, MD, Amin Alousi, MD, Betul Oran, MD, Paolo Anderlini, MD, Stefan O Ciurea, MD, Chitra M. Hosing, MD, Uday R Popat, MD, Elias Jabbour, MD, Richard E Champlin, MD, Roland Bassett

Blood (2013) 122 (21): 541.

https://doi.org/10.1182/blood.V122.21.541.541

Published: 2013

NARROW

Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL)

Modified-CVAD Or Modified-Cbad Compared To High Dose Cyclophosphamide For Peripheral Blood Stem Cell Mobilization In Patients With Multiple Myeloma

A Lower Dose Of Melphalan (140 mg/m 2 ) As Preparative Regimen For Multiple Myeloma In Patients >65 Or With Renal Dysfunction

Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan ( 90 YIT)

Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis

Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosuppression

Email alerts

ASH Publications

American Society of Hematology

Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL)

Modified-CVAD Or Modified-Cbad Compared To High Dose Cyclophosphamide For Peripheral Blood Stem Cell Mobilization In Patients With Multiple Myeloma

A Lower Dose Of Melphalan (140 mg/m 2 ) As Preparative Regimen For Multiple Myeloma In Patients >65 Or With Renal Dysfunction

Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan ( 90 YIT)

Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis

Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosuppression

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only